Tandem Diabetes Care Q2 sales up 174%; guidance raised

Tandem Diabetes Care (NASDAQ:TNDM) Q2 results ($M): Sales: 93.3 (+173.6%).

Net income: (1.5) (+97.5%); EPS: (0.03) (+97.4%).

Non-GAAP EBITDA margin: 13%.

Pump shipments: 21,258 (+290%).

2019 guidance: Sales: $350M – 365M from $300M – 315M; non-GAAP EBITDA margin: 5 – 10% from breakeven to positive.

Shares up 10% after hours.

Previously: Tandem Diabetes Care EPS beats by $0.21, beats on revenue(Aug. 1)

https://seekingalpha.com/news/3485816-tandem-q2-sales-174-percent-guidance-raised-shares-10-percent-hours